PLEASANTON, CA -- (MARKET WIRE) -- February 12, 2007 -- Lipid Sciences, Inc. (NASDAQ: LIPD) announced today that Dr. Philip Barter and Dr. John Kastelein, two pre-eminent researchers and clinical trial experts in the field of lipids and lipoproteins, have joined the Company's Scientific Advisory Board. They now become part of a team headed by Dr. H. Bryan Brewer, an internationally-recognized lipid metabolism expert. Dr. Brewer is the architect of Lipid Sciences' HDL Therapy platform (HDL Selective Delipidation and HDL mimetic peptides) designed to develop potential treatments to reverse atherosclerotic plaque in the coronary arteries. If left untreated, these plaques are highly vulnerable to rupture which can lead to a heart attack or stroke.
